Soligenix Inc. Reports Positive Interim Results for HyBryte(TM) in Early-Stage CTCL Treatment

Soligenix Inc. (NASDAQ: SNGX) has shared promising interim results from its ongoing investigator-initiated study of HyBryte(TM), a potential breakthrough in the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The study, under the direction of Ellen Kim, MD, from the Penn Cutaneous Lymphoma Program, focuses on the effectiveness of HyBryte(TM) when used twice weekly for up to 54 weeks in patients suffering from early-stage mycosis fungoides, a common type of CTCL.

At the 18-week mark, the preliminary outcomes have been positive, signaling a ray of hope for patients who have seen few new FDA-approved treatments in the last ten years. Current treatment modalities often carry significant risks, underscoring the importance of HyBryte(TM)'s development as a safer, more effective alternative. The collaboration between the Cutaneous Lymphoma Foundation and Soligenix to disseminate these findings underscores the therapy's potential to address a critical gap in CTCL care.

For those interested in following Soligenix's progress and the latest updates on HyBryte(TM), more information can be found by visiting https://ibn.fm/SNGX. This development represents a significant step forward in the quest for innovative treatments for CTCL, offering new hope to patients and healthcare providers alike.